EMA and HTA bodies jointly review a proposed EU framework for patient preference studies

Published date02 November 2020
Subject MatterMedical Devices,Life Sciences,Health Information Technologies,Risk Assessment,Pharmaceutical Industry,European Medicines Agency (EMA)
AuthorElisabethann Wright
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT